Macrophage Activation Syndrome
Arthritis & Rheumatology · 2025-04 · 77 (4) · 367-379
DOI: 10.1002/art.43052 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Arthritis & Rheumatology, online erschienen am 12.12.2024. Verfasst von Peter A Nigrovic. Beteiligte Einrichtung: Boston Children's Hospital and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Macrophage Activation Syndrome. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 86 Literaturangaben. Gefördert von: Lupus Research Alliance, NIAMS NIH HHS, National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Abstract (Originalsprache)
Macrophage activation syndrome (MAS) is a state of immune hyperactivation that can result in life‐threatening multisystem end‐organ dysfunction. Often termed a “cytokine storm,” MAS occurs among the rheumatic diseases most typically in Still's disease but also in systemic lupus erythematosus and Kawasaki disease. MAS can also accompany infection, malignancy, and inborn errors of immunity. This review provides a practical, evidence‐based guide to the understanding, recognition, and management of MAS in children and adults, with a primary focus on MAS complicating Still's disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Boston Children's Hospital and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
ORCID-Profile: Peter A Nigrovic
Förderung
- Lupus Research Alliance
- NIAMS NIH HHS
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Nigrovic, P. A. (2025). Macrophage Activation Syndrome. Arthritis & Rheumatology, 77(4), 367-379. https://doi.org/10.1002/art.43052
Vancouver
Nigrovic PA. Macrophage Activation Syndrome. Arthritis & Rheumatology. 2025;77(4):367-379. doi:10.1002/art.43052
BibTeX
@article{Nigrovic2025,
author = {Nigrovic, Peter A},
title = {Macrophage Activation Syndrome},
journal = {Arthritis & Rheumatology},
year = {2025},
volume = {77},
number = {4},
pages = {367--379},
doi = {10.1002/art.43052}
}
EUVIMED